Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group (Q73293587)
Jump to navigation
Jump to search
scientific article published on 01 November 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group |
scientific article published on 01 November 2000 |
Statements
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group (English)
K Saag
D van der Heijde
C Fisher
A Samara
J Bolognese
R Sperling
1 November 2000